OCUL · Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

14 Crosby Drive, Bedford, MA, 01730, United States
Biotechnology
Healthcare

Market Cap

1.226B

52 Wk Range

$5.54 - $16.44

Previous Close

$5.86

Open

$5.76

Volume

2,895,423

Day Range

$5.54 - $5.95

Enterprise Value

837.9M

Cash

530.6M

Avg Qtr Burn

-65.62M

Insider Ownership

0.91%

Institutional Own.

96.95%

Qtr Updated

Sep 30th 2026